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ScienceDirectMolecular recognition by RNA aptamers has been exploited to
control gene expression in response to small molecules in
mammalian cells. These mammalian synthetic riboswitches
offer attractive features such as small genetic size and lower
risk of immunological complications compared to protein-
based transcriptional gene switches. The diversity of gene
regulatory mechanisms that involve RNA has also inspired the
development of mammalian riboswitches that harness various
regulatory mechanisms. In this report, recent advances in
synthetic riboswitches that function in mammalian cells are
reviewed focusing on the regulatory mechanisms they exploit
such as mRNA degradation, microRNA processing, and
programmed ribosomal frameshifting.
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Introduction
Envisioned practical applications of mammalian synthetic
biology frequently require gene switches that recognize
endogenous or exogenous chemical signals and turn on or
turn off expression of proteins, which in turn regulate
synthetic genetic circuits inside the cell. These chemical
gene switches need to be flexible enough to be tailored to
diverse chemical species, engineered to function as
ON-switch or OFF-switch, fine-tuned to adjust the
sensitivity, and have a minimal genetic and metabolic
footprint. Protein-based engineered transcription factors
(TFs), such as Tet-ON and Tet-OFF systems derived
from a bacterial TF, are among the most widely used tools
to control mammalian gene expression in response to
small molecule triggers [1]. However, there are a number
of drawbacks of TF-based gene switches as generally
applicable switches for mammalian and biomedicalCurrent Opinion in Chemical Biology 2019, 52:72–78 applications [2–4]: (i) adapting an engineered TF to
respond to a new compound is challenging, (ii) expression
of engineered TFs can trigger immunogenicity, (iii)
genetic size and expression of an engineered TF can
burden the host cell or the vector, and (iv) switch perfor-
mance can be influenced by the expression level of the
TF; therefore, optimization may be required. RNA
aptamers for desired ligands can be obtained relatively
easily by in vitro selection (SELEX) [5,6]; therefore,
riboswitches can potentially be engineered to respond
to a variety of compounds more readily than engineered
TFs. Moreover, aptamers are typically small (20 to
100 nt). Even with the additional nucleotides necessary
to regulate gene expression, genetic footprints of
riboswitches (few hundred nt) are small enough to satisfy
vectors that have limited capacity (e.g. adeno associated
virus). Furthermore, the lack of any translated proteins is
expected to result in lower immunogenicity and
metabolic burden on the host cell.
In 1998, Werstuck and Green [7] demonstrated that
insertion of an RNA aptamer selected to bind the
Hoechst dye H33342 in the 50 untranslated region of
mRNA allows repression of gene expression in response
to the ligand in CHO cells, presumably by blocking
ribosome binding or scanning. It should be noted that
this work predated the discovery of natural bacterial
riboswitches [8,9], demonstrating that small molecules
can directly and specifically affect gene expression in the
absence of mediator proteins. Importantly, RNA
aptamer-based regulation of gene expression allows
bioengineers to harness the rich diversity of gene
regulatory mechanisms that involve RNA, for example,
translation initiation, RNA interference and microRNAs,
and RNA splicing. For each RNA mediated gene
regulatory mechanism, there are multiple ways to couple
its outcome with aptamer–ligand interaction, further
enriching the potential diversity of synthetic riboregu-
lators. An excellent review on RNA-based gene switches
in mammalian cells was recently published by Ausla¨nder
and Fussenegger [10]. Therefore, this article reviews
more recent developments in synthetic mammalian
riboswitches with a focus on the diversity of the regula-
tory mechanisms harnessed by the riboswitches.
Controlling mRNA cleavage by aptazymes
In 2004, Yen et al. demonstrated chemical regulation of
gene expression in mammalian cells by embedding a
hammerhead ribozyme in the untranslated regions
(UTRs) of an mRNA [11]. As the 50 and 30 UTRs arewww.sciencedirect.com
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self-cleavage within the mRNA was expected to suppress
gene expression. Addition of toyocamycin to the cell
culture medium resulted in nonspecific incorporation of
the antiviral nucleotide analog into the mRNA and
statistical inactivation of the ribozyme activity [12]. While
the ribozyme was not specifically regulated by a small
molecule via an aptamer, this work paved the way for the
subsequent riboswitches that employ allosterically regu-
lated ribozymes (aptazymes) embedded in the 50 and/or 30
UTR to chemically regulate gene expression in mamma-
lian cells (Figure 1a) [13–16]. This strategy continues to
be popular, and the recent advances highlight new
approaches to design and optimize aptazymes.
Earlier aptazyme-based riboswitches in mammalian cells
were designed via trial-and-error, or based on medium-
throughput or high-throughput screening in bacteria or
yeast systems. However, it has been reported that ribozyme
activity in living cells are not highly correlated among
different cell types (bacteria, yeast, or mammalian cells)
which is understandable considering the differences in
translational mechanism, intracellular environment
(RNA binding proteins, ribonucleases, etc.), and mode of
gene regulation by ribozymes in different cell types [17].
Because high-throughput screening of riboswitches
directly in mammalian cells is technically challenging,Figure 1
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Regulatory mechanisms of synthetic riboswitches. (a) Aptazymes inserted in
chemically controlled self-cleavage. (b) Schematic illustration of the ‘molecu
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www.sciencedirect.com alternative design strategies focusing on aptazymes that
function in mammalian cells are desirable.
The Farzan group demonstrated an intriguing strategy
that combines empirical experimental data with quanti-
tative modeling [18]. They first synthesized a panel of
32 aptazymes and measured their riboswitch performance
in cultured mammalian cells, and attempted to correlate
the experimental results with various design parameters
such as calculated annealing energy and the number of
hydrogen bonds in the communication module. The
researchers concluded that the proximity of base pairing
(or lack thereof) within the communication module to
the ribozyme affects the ribozyme activity, and
devised ‘Weighted Hydrogen Bond Score (WHBS)’ as a
calculable parameter that correlates with the ribozyme
performance. They used WHBS as a guide to design
aptazyme-based riboswitches using three aptamers with
good switching characteristics [18]. It remains to be seen
if the strategy can be extrapolated to different aptamers,
ribozymes, and aptazyme architectures.
Dohno et al. addressed the aptazyme design problem with
a unique approach [19]. Instead of starting from an
existing aptamer, they started with a rationally designed
molecule targeted to mismatched DNA/RNA sequences.
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 untranslated regions of mRNAs regulate the integrity of mRNA via
lar glue’ that activates a hammerhead ribozyme by restoring loop–loop
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74 Synthetic biologylinker (Z-NCTS) designed by the group is known to bind
XGG/XGG mismatches in DNA and RNA through
Watson-Crick type hydrogen bonding between the
naphthyridine moieties with the unpaired guanines
[20]. They used this ligand as a ‘molecular glue’ to induce
a tertiary contact between loops I and II of a hammerhead
ribozyme that is critical for ribozyme activity (Figure 1b).
The tertiary contact between the two loops was disrupted
by introducing an AGG/UGG mismatch that is recog-
nized by Z-NCTS. The engineered ribozyme was
inserted into the 30 UTR of an mRNA encoding firefly
luciferase whose expression was reduced by 4-fold upon
addition of Z-NCTS (0.6 mM) in HeLa cells. While it is
notable that the switching was observed with a low ligand
concentration, Z-NCTS exhibited cellular toxicity
(LC50 = 0.8 mM) probably due to nonspecific interactions
with cellular RNAs.
In contrast to these rational or semi-rational design
efforts, high-throughput screening of aptazymes has
mostly been executed in Escherichia coli or SaccharomycesFigure 2
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Current Opinion in Chemical Biology 2019, 52:72–78 cerevisiae. However, screening is generally labor and cost
intensive while yielding sequence information for a
handful of ‘hits’. Screening also yields limited sequence-
–function information that can be exploited for further
optimization or library design. To address the lack of
comprehensive sequence–function relationship data for
ribozymes, we developed an in vitro high-throughput
ribozyme assay method using deep sequencing (Figure 2)
[21,22,23]. A library of ribozyme or aptazyme mutants
are transcribed in vitro in a single tube as a mixture, and
the resulting ribozymes (cleaved or uncleaved) are
converted to DNA templates for deep sequencing. The
number of cleaved and uncleaved reads for each ribozyme
variant are then counted to calculate cleavage efficiency
under the reaction condition. This strategy yields a
complete sequence–function relationship for all members
of the ribozyme library up to 104 variants or more [24],
depending on library preparation and sequencing output.
This method can unambiguously identify functional
aptazymes if they exist, and provide a broader view of
the sequence–function relationship that can be used toAAAA
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quencing. An aptazyme library is prepared as a DNA mixture which is
then converted to DNA sequencing templates by reverse transcription
d fragments for every mutant in the library from which cleavage
nts in the presence and absence of the ligand reveals aptazyme
www.sciencedirect.com
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aptazyme design. We used deep sequencing to identify
guanine-activated ribozymes based on an HDV-like
ribozyme which were subsequently used to control gene
expression in HEK 293 cells [21]. Use of a low Mg2+
concentration during in vitro transcription may have con-
tributed to the positive correlation of the ribozyme
activity in vitro and in mammalian cells. Similar methods
were also used to fine tune mammalian gene expression
levels [25] and to screen for active ribozymes (but not
aptazymes) directly in mammalian cells [26].
Controlling ribosomal frameshifting by
aptamers
Programmed -1 ribosomal frameshifting (-1PRF) [27] can
result in translation of an alternative polypeptide from an
mRNA by shifting the translation reading frame by -1
nucleotide. A canonical -1PRF element consists of a 7-nt
slippery sequence X XXY YYZ (trinucleotides XXY and
YYZ representing the original frame and XXX YYY
representing the -1 frameshift) followed by a stable
secondary structure such as a pseudoknot or a stem-loop.
The Chang group first controlled -1PRF in mammalian
cells (Figure 3a) by incorporating theophylline and
S-adenosyl-L-homocysteine (SAH) aptamers [28]. An
ON/OFF ratio of 6 was reported but the frameshifting
efficiency (FE) remained low. The same group used
another -1PRF stimulating pseudoknot from SARS
coronavirus to engineer theophylline inducible -1PRF
switches with up to fivefold activation of gene expression
[29]. More recently, Matsumoto et al. used the analogs of
naphthyridine carbamate tetramers described above to
control the formation of a pseudoknot, thereby
chemically inducing -1PRF (Figure 3a, top) [30].
Although up to 9-fold activation was observed in HeLa
cells, the maximum FE was low (3.2%) in the presence of
the pseudoknot inducing ligand. It is possible that the
toxicity of the ligand prevented observation of higher FEs
in HeLa cells, as an FE as high as 24% was observed in
rabbit reticulocyte lysate.
Controlling microRNA maturation pathway by
aptamers
Besides controlling translation via an aptamer embedded
in the targeted mRNA, another strategy aims to control
the microRNA (miRNA) processing pathway by an RNA
aptamer. The miRNA product subsequently targets one
or more mRNAs in trans. An et al. first demonstrated that
an aptamer incorporated in a miRNA precursor allows
chemical regulation of RNA interference (RNAi), in this
case, by modulating the Dicer mediated cleavage of a
short-hairpin RNA (shRNA) [31]. The Smolke group has
developed an alternative strategy that controls the Drosha
mediated processing of primary miRNA substrates by
embedding an RNA aptamer in the vicinity of the Drosha
cleavage site [32]. Binding of the ligand to the aptamer
inhibits Drosha cleavage and upregulates the expressionwww.sciencedirect.com of the gene targeted by the miRNA. Recently, the group
adapted an aptamer that they selected for (6R)-folinic
acid (FA) to control a synthetic miRNA precursor
targeting IL-2 receptors (Figure 3b) [33]. Although the
modulation of the targeted gene expression by the ligand
was rather modest (up to 35% activation), it was sufficient
to observe a robust regulation of cell proliferation.
The Suess group reported a new strategy to control the
Dicer processing by inserting an aptamer that binds to
TetR protein [34] near the cleavage site blocking the
reaction in the presence of TetR [35]. They showed that
addition of the TetR ligand doxycycline dissociates TetR
from the miRNA precursor and increases the formation of
the mature miRNA (Figure 3c). Doxycycline was able to
tightly control the mature miRNA level (1%–40% relative
to unmodified miRNA precursor), although the ON/OFF
ratio of the targeted reporter gene was more moderate
(3). Although this system requires an exogenous protein
factor, it allows the use of doxycycline which has been
used extensively in mammalian cells and animals.
The Pei group adapted another Drosha modulation
strategy originally reported by our group [36,37] to
control endogenous gene expression in cancer cell lines
to induce apoptosis. A theophylline activated aptazyme
was inserted between an inhibitory strand that blocks
the 30 single-stranded region of the pri-miRNA,
thereby preventing the RNA from being processed
by Drosha (Figure 3d). The researchers targeted
MAP4K4 in HepG2 cells [38] and Bcl-2 in MCF-7 cells
[39], and observed fourfold to fivefold increase in
apoptosis.
Controlling other gene regulatory processes
by aptamers
Vogel et al. showed that exon skipping can be
controlled by a tetracycline RNA aptamer inserted
near the 30 splice site along with a suicide exon
(Figure 3e) [40]. Tetracycline induces exon skipping
resulting in 5-fold activation of gene expression. In
combination with an aptazyme device, the dynamic
range increased to 7-fold in HEK 293 cells.
An mRNA can be targeted by an endogenous miRNA by
inserting one or more miRNA target sequences in the
30 UTR, a strategy sometimes used to achieve cell
type-dependent gene expression. Mou et al. controlled
the accessibility of the miRNA target sequence by an
aptamer embedded near the target site in the mRNA
[41]. Addition of tetracycline occluded the miRNA target
site resulting in upregulation of gene expression
(Figure 3f). The performance of the switch, as expected,
was dependent on the miRNAs and cell types used, but
theyobservedtight regulationofgene expressionwith upto
19-fold activation in HeLa cells with a miR-21 target site.Current Opinion in Chemical Biology 2019, 52:72–78
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Regulatory mechanisms of synthetic riboswitches. (a) Regulation of -1PRF by a small molecule via stabilizing the downstream pseudoknot element
or interfering with formation of the upstream stem loop that negatively affect -1PRF. (b) Interfering with the cleavage of pri-miRNA by Drosha by
an aptamer–ligand complex near the cleavage site. (c) TetR protein bound to the aptamer embedded in pre-miRNA prevents Dicer cleavage.
Addition of doxycycline removes TetR and upregulates miRNA maturation. (d) The 30 single-stranded region of a pri-miRNA that is necessary for
Drosha processing is unmasked by an aptazyme. (e) An aptamer incorporated near the 30 splice site of an intron followed by a suicide exon
containing a stop codon can induce exon skipping in the presence of the aptamer ligand. (f) A miRNA target site inserted in the 30 UTR of an
mRNA is occluded by aptamer–ligand interaction, resulting in increased protein expression.
Current Opinion in Chemical Biology 2019, 52:72–78 www.sciencedirect.com
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The diversity of gene regulatory mechanisms that involve
RNA has and will continue to inspire synthetic RNA-
based gene switches in mammalian cells. It can be antici-
pated that riboswitches based on different regulatory
mechanisms have advantages for different applications.
For example, miRNA-based riboswitches are more con-
venient for controlling endogenous gene expression
because they operate in trans as opposed to the UTR
embedded aptazymes that function in cis. However, the
existing mammalian riboswitches still exhibit poor and
variable dynamic range and ligand sensitivity compared
to the conventional TF-based gene switches. With fur-
ther optimization and increasing availability of new apta-
mers and ligands for cellular applications, synthetic ribos-
witches should emerge as useful tools in synthetic biology
of mammalian cells.
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